1816 related articles for article (PubMed ID: 27497913)
21. Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells.
González H; Contreras F; Pacheco R
J Neuroimmune Pharmacol; 2015 Dec; 10(4):561-75. PubMed ID: 26018603
[TBL] [Abstract][Full Text] [Related]
22. Cell death mechanisms in Parkinson's disease.
Jellinger KA
J Neural Transm (Vienna); 2000; 107(1):1-29. PubMed ID: 10809400
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
24. The understanding of Parkinson's disease through genetics and new therapies.
Uwishema O; Onyeaka H; Badri R; Yücel AN; Korkusuz AK; Ajagbe AO; Abuleil A; Chaaya C; Alhendawi BHM; Chalhoub E
Brain Behav; 2022 May; 12(5):e2577. PubMed ID: 35451243
[TBL] [Abstract][Full Text] [Related]
25. Parkinson's disease is an autoimmune disease: A reappraisal.
Bonam SR; Muller S
Autoimmun Rev; 2020 Dec; 19(12):102684. PubMed ID: 33131704
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
27. Translational molecular imaging and drug development in Parkinson's disease.
Haider A; Elghazawy NH; Dawoud A; Gebhard C; Wichmann T; Sippl W; Hoener M; Arenas E; Liang SH
Mol Neurodegener; 2023 Feb; 18(1):11. PubMed ID: 36759912
[TBL] [Abstract][Full Text] [Related]
28. Defining the contribution of neuroinflammation to Parkinson's disease in humanized immune system mice.
Manocha GD; Floden AM; Puig KL; Nagamoto-Combs K; Scherzer CR; Combs CK
Mol Neurodegener; 2017 Feb; 12(1):17. PubMed ID: 28196514
[TBL] [Abstract][Full Text] [Related]
29. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
30. Neuron-Astrocyte Interactions in Parkinson's Disease.
Miyazaki I; Asanuma M
Cells; 2020 Dec; 9(12):. PubMed ID: 33297340
[TBL] [Abstract][Full Text] [Related]
31. Glymphatic System Dysfunction and Sleep Disturbance May Contribute to the Pathogenesis and Progression of Parkinson's Disease.
Scott-Massey A; Boag MK; Magnier A; Bispo DPCF; Khoo TK; Pountney DL
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361716
[TBL] [Abstract][Full Text] [Related]
32. An inflammatory pathomechanism for Parkinson's disease?
Wersinger C; Sidhu A
Curr Med Chem; 2006; 13(5):591-602. PubMed ID: 16515523
[TBL] [Abstract][Full Text] [Related]
33. Novel Targets for Parkinson's Disease: Addressing Different Therapeutic Paradigms and Conundrums.
Rane P; Sarmah D; Bhute S; Kaur H; Goswami A; Kalia K; Borah A; Dave KR; Sharma N; Bhattacharya P
ACS Chem Neurosci; 2019 Jan; 10(1):44-57. PubMed ID: 29957921
[TBL] [Abstract][Full Text] [Related]
34. Is Parkinson's disease an autoimmune disorder of endogenous vasoactive neuropeptides?
Staines DR
Med Hypotheses; 2007; 69(6):1208-11. PubMed ID: 17562359
[TBL] [Abstract][Full Text] [Related]
35. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
36. Bee venom for the treatment of Parkinson's disease: How far is it possible?
Awad K; Abushouk AI; AbdelKarim AH; Mohammed M; Negida A; Shalash AS
Biomed Pharmacother; 2017 Jul; 91():295-302. PubMed ID: 28477460
[TBL] [Abstract][Full Text] [Related]
37. Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy.
de Araújo FM; Cuenca-Bermejo L; Fernández-Villalba E; Costa SL; Silva VDA; Herrero MT
Cell Mol Neurobiol; 2022 Jul; 42(5):1283-1300. PubMed ID: 33387119
[TBL] [Abstract][Full Text] [Related]
38. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
39. Etiology and pathogenesis of Parkinson's disease.
Olanow CW; Tatton WG
Annu Rev Neurosci; 1999; 22():123-44. PubMed ID: 10202534
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
